No Data
LakeShore Biopharma Initiates Biologics License Application Of PIKA Rabies Vaccine To The Drug Regulatory Authority Of Pakistan
Lacklustre Performance Is Driving LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) 66% Price Drop
LakeShore Biopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
LakeShore Biopharma Advances With Rabies Vaccine Trial
LakeShore Biopharma Receives Phase III Trial Approval In China For Simplified Four-Dose YSJA Rabies Vaccine Regimen; Aims To Enhance Patient Adherence And Reduce Costs While Maintaining Immunogenicity
LakeShore Biopharma Shares Higher on Unchanged FY Guidance
No Data
No Data